Adie Viljoen

5.0k total citations · 2 hit papers
98 papers, 3.3k citations indexed

About

Adie Viljoen is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Adie Viljoen has authored 98 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Endocrinology, Diabetes and Metabolism, 34 papers in Surgery and 25 papers in Molecular Biology. Recurrent topics in Adie Viljoen's work include Diabetes Treatment and Management (31 papers), Lipoproteins and Cardiovascular Health (27 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (24 papers). Adie Viljoen is often cited by papers focused on Diabetes Treatment and Management (31 papers), Lipoproteins and Cardiovascular Health (27 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (24 papers). Adie Viljoen collaborates with scholars based in United Kingdom, United States and Canada. Adie Viljoen's co-authors include Ildiko Lingvay, Anthony S. Wierzbicki, Richard E. Pratley, Vanita R. Aroda, J Lüdemann, Andrea Navarria, Catharine M. Sturgeon, Sue D. Pedersen, Iichiro Shimomura and Thomas A. Wadden and has published in prestigious journals such as The Lancet, PLoS ONE and Diabetes.

In The Last Decade

Adie Viljoen

93 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

2021 806 citations Adie Viljoen, Ildiko Lingvay et al. profile →
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

2018 559 citations Richard E. Pratley, Vanita R. Aroda et al. profile →

Peers

Countries citing papers authored by Adie Viljoen

Since Specialization

Citations

This map shows the geographic impact of Adie Viljoen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adie Viljoen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adie Viljoen more than expected).

Fields of papers citing papers by Adie Viljoen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adie Viljoen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adie Viljoen. The network helps show where Adie Viljoen may publish in the future.

Co-authorship network of co-authors of Adie Viljoen

This figure shows the co-authorship network connecting the top 25 collaborators of Adie Viljoen. A scholar is included among the top collaborators of Adie Viljoen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adie Viljoen. Adie Viljoen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Leflunomide as an alternative csDMARD for rheumatoid arthritis in a resource-constrained setting: A real-life experience 2025 ·South African Medical Journal ·(unknown), Adie Viljoen	0
2	Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3 2023 ·Diabetes Therapy ·Adie Viljoen, Kevin M. Pantalone, Rodolfo J. Galindo, Xuewei Cui, Ruth Huh, (unknown), Laura Fernández Landó, Hiren Patel	3
3	Patients with Type 2 Diabetes Reach Glycaemic Targets Faster with Tirzepatide Compared to Semaglutide and Titrated Insulin Degludec 2023 ·Diabetologie und Stoffwechsel ·Adie Viljoen, Kevin M. Pantalone, Rodolfo J. Galindo, Xuewei Cui, Ruth Huh, Laura Fernández Landó, (unknown), Baptist Gallwitz	0
4	The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK 2022 ·The European Journal of Health Economics ·Adie Viljoen, Barrie Chubb, Samuel J. P. Malkin, (unknown), Barnaby Hunt, Stephen C. Bain	5
5	Colesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia 2022 ·Expert Opinion on Pharmacotherapy ·(unknown), Adie Viljoen, Anthony S. Wierzbicki	9
6	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice 2022 ·Diabetes Therapy ·Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Debbie Hicks, (unknown), Zaheer Yousef, Umesh Dashora, Adie Viljoen, (unknown), W. David Strain	7
7	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies 2021 ·Vascular Health and Risk Management ·(unknown), Adie Viljoen, Anthony S. Wierzbicki	21
8	An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg 2021 ·Diabetes Obesity and Metabolism ·Richard E. Pratley, Andrei‐Mircea Catarig, Ildiko Lingvay, Adie Viljoen, (unknown), Jack Lawson, Barrie Chubb, Anders Gorst‐Rasmussen, (unknown)	17
9	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses 2020 ·BMJ Open ·Richard E. Pratley, Vanita R. Aroda, Andrei‐Mircea Catarig, Ildiko Lingvay, J Lüdemann, Emre Yıldırım, Adie Viljoen	13
10	Clinical care and other categories posters: Incretin therapies 2019 ·Diabetic Medicine ·T. Yamada, (unknown), Nobuhiro Shojima, Toshimasa Yamauchi, Takashi Kadowaki, Adie Viljoen, (unknown), Pierre Johansen, (unknown), Barnaby Hunt, Steve Baín	1
11	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice 2019 ·Diabetes Therapy ·(unknown), Steve Baín, Debbie Hicks, (unknown), Dipesh Patel, Marc Evans, (unknown), (unknown), Nicola Milne, Adie Viljoen, John Wilding	37
12	Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres 2018 ·International Journal of Clinical Practice ·Anthony S. Wierzbicki, Adie Viljoen, (unknown), Steven C. Martin, Martin Crook, Tim Reynolds	2
13	Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin 2016 ·Kidney International ·Jonathan Wong, Sivakumar Sridharan, Jocelyn Berdeprado, E. Vilar, Adie Viljoen, David Wellsted, Ken Farrington	45
14	Renal biomarkers for the prediction of cardiovascular disease 2015 ·Current Opinion in Cardiology ·Supriya Joshi, Adie Viljoen	8
15	Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function 2012 ·Diabetes Research and Clinical Practice ·Dhruv K. Singh, Peter Winocour, (unknown), (unknown), Adie Viljoen, (unknown), Ken Farrington	29
16	Evidence of biochemical hyperandrogenism in women: The limitations of serum testosterone quantitation 2012 ·Journal of Obstetrics and Gynaecology ·(unknown), Claire L. Meek, Adie Viljoen	7
17	Triglycerides 2012 ·Current Opinion in Cardiology ·Anthony S. Wierzbicki, (unknown), Adie Viljoen, Dimitri P. Mikhailidis	29
18	A practical approach to lipid management in the elderly 2011 ·The journal of nutrition health & aging ·Adie Viljoen	1
19	Investigating mixed hyperlipidaemia 2011 ·BMJ ·Adie Viljoen, Anthony S. Wierzbicki	2
20	Percentage non-caeruloplasmin bound copper 2007 ·Clinical Biochemistry ·Patrick J. Twomey, Anthony S. Wierzbicki, Ivan House, Adie Viljoen, Tim Reynolds	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact